Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SB nicotine patch European launch

This article was originally published in The Tan Sheet

Executive Summary

SmithKline Beecham is introducing NiQuitin CQ nicotine patches in the U.K., Belgium and Sweden for pharmacy-only (nonprescription) sale, the company says Nov. 23. SB is devoting $19 mil. to its U.K. marketing campaign, with ads by Ogilvie & Mather. The product is accompanied by a "Committed Quitters" behavior modification program similar to that available with SB's identical U.S. product Nicoderm CQ. NiQuitin will be premium priced in the U.K. to Pharmacia & Upjohn's Nicorette and Novartis' Nicotinell lines. Manufactured by Alza and licensed from Hoescht Marion Roussel, the NiQuitin/NicoDerm products are identical to the Nicabate patch sold in Australia and Sweden, which SB purchased from HMR in September. SB has global marketing rights to the Alza product except in Canada and Korea, where the patch is sold by HMR. Smoking cessation patches have been sold without prescription in European pharmacies for about six years
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel